Disease modifying treatment trials in Parkinson’s disease: how to balance expectations and interests of patients, physicians and industry partners?
Abstract Background The advent of therapeutic strategies designed to modify the disease course in Parkinson’s disease has raised great expectations in the currently conducted clinical trials. However, we see ethical challenges in the cooperation of industry and clinical partners, specifically eviden...
Main Authors: | D. Berg, K. Eggert, B. Haslinger, J. Kassubek, B. Mollenhauer, K. Reetz, A. Rogge, E. Schaeffer, L. Tönges, K. E. Zeuner |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-11-01
|
Series: | Neurological Research and Practice |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s42466-020-00076-y |
Similar Items
-
Protein Binding Partners of Dysregulated miRNAs in Parkinson’s Disease Serum
by: Wolfgang P. Ruf, et al.
Published: (2021-04-01) -
Quantitative analysis of the blood transcriptome of young healthy pigs and its relationship with subsequent disease resilience
by: Kyu-Sang Lim, et al.
Published: (2021-08-01) -
Challenges of Integrative Disease Modeling in Alzheimer's Disease
by: Sepehr Golriz Khatami, et al.
Published: (2020-01-01) -
Neglected tropical disease: Why we need to prioritize them more
by: Ruby Dhar, et al.
Published: (2022-10-01) -
Nutrition Challenges of Patients with Alzheimer’s Disease and Related Dementias: A Qualitative Study from the Perspective of Caretakers in a Mental National Referral Hospital
by: Kigozi E, et al.
Published: (2021-07-01)